Peptic Ulcer Disease involves sores developing in the lining of the stomach, lower esophagus, or small intestine. This mucosal damage happens when aggressive factors like gastric acid and pepsin overwhelm defensive mechanisms. The primary goals of pharmacological treatment are to relieve pain, promote ulcer healing, and prevent recurrence and complications such as bleeding or perforation. Therapy generally focuses on either reducing gastric acid secretion or enhancing mucosal defense.
Proton Pump Inhibitors are the most potent suppressors of gastric acid secretion available. They work by irreversibly binding to the H+/K+ ATPase enzyme system on the surface of gastric parietal cells.
PPIs should ideally be taken 30 to 60 minutes before the first meal of the day to ensure peak plasma levels coincide with the maximal activation of proton pumps.
Histamine-2 receptor antagonists competitively block histamine receptors on parietal cells, which suppresses basal and nocturnal acid secretion. While less potent than proton pump inhibitors, drugs like cimetidine, famotidine, and ranitidine provide effective relief for mild to moderate acid-related conditions. Nurses must monitor for central nervous system side effects such as confusion, particularly in elderly patients with impaired renal function.
Antacids are alkaline substances that chemically neutralize existing hydrochloric acid in the stomach lumen, rapidly raising gastric pH. They offer fast, short-term relief for dyspepsia and acute ulcer pain. Different formulations contain different metallic ions, each with distinct bowel movement side effects:
Cytoprotective agents shield the gastrointestinal mucosa from the damaging effects of acid and pepsin rather than neutralizing acid directly. Sucralfate reacts with gastric acid to form a sticky, viscous gel that binds selectively to ulcer craters, forming a protective barrier for up to six hours. Bismuth subsalicylate provides antibacterial action and helps coat the mucosal lining. Misoprostol, a synthetic prostaglandin E1 analog, increases mucus and bicarbonate secretion while reducing acid production, making it particularly useful for preventing NSAID-induced ulcers.
Helicobacter pylori is a gram-negative bacterium responsible for a significant majority of peptic ulcers. Eradication requires combination therapy to prevent antimicrobial resistance and ensure treatment success. Standard first-line treatment typically involves triple therapy consisting of a proton pump inhibitor combined with two antibiotics, such as clarithromycin and amoxicillin, taken for 10 to 14 days. If local resistance rates to clarithromycin are high, quadruple therapy containing bismuth, a PPI, and two antibiotics is preferred.
Nurses play a vital role in managing patients with peptic ulcer disease by assessing pain patterns, monitoring for adverse drug effects, and reinforcing adherence to complex medication schedules. Patient education should emphasize completing the full course of prescribed antibiotics, avoiding smoking and alcohol which irritate the gastric mucosa, and limiting the use of ulcerogenic drugs like NSAIDs. Nurses must also teach patients to report warning signs such as black tarry stools, persistent vomiting, or sharp abdominal pain immediately.